Solasia Pharma K.K. (4597.T)

27.00 +1.00 (+3.85%) At close: 03:15PM JST

Solasia Pharma K.K.

Sumitomo Fudosan Shiba-Koen Tower
4th Floor 2-11-1, Shiba-koen Minato-ku
Tokyo 105-0011
Japan
81 3 5843 8045
https://www.solasia.co.jp

Sector(s): Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Full Time Employees: 24

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Yoshihiro Arai	President, CEO & Representative Director	N/A	N/A	1960
Mr. Toshio Miyashita	CFO, GM of Management Headquarters & Director	N/A	N/A	1967
Yasumitsu Shimada	Accounting Manager	N/A	N/A	N/A
Yasuaki Manabe	Head of Marketing Division	N/A	N/A	N/A
Mr. Koji Shinozaki	Head of Business Development Department	N/A	N/A	N/A
Fumiko Nagahama	Head of Product Development Division	N/A	N/A	N/A
Hikaru Osawa	Head of Production Management Division	N/A	N/A	N/A
Wataru Kobayashi	Head of Reliability Assurance Division	N/A	N/A	N/A

Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in JPY.

Description

Solasia Pharma K.K. engages in the development and marketing of oncology drugs in Japan and other Asian countries. The company offers episil oral liquid for the protection and relief of oral pain associated with oral mucositis/stomatitis caused by chemotherapy and radiotherapy for cancer; Sancuso, a transdermal delivery system that delivers granisetron, an anti-emetic into the patient's bloodstream for the treatment of chemotherapy induced nausea and vomiting; and Darvias injection, and antineoplastic agent/organic arsenic product indicated for relapsed or refractory peripheral T-cell lymphoma. It is also involved in the development of SP-04, a chemotherapy induced peripheral neuropathy which is in pre-clinical stage. The company was founded in 2006 and is based in Tokyo, Japan.

Corporate Governance

Solasia Pharma K.K.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.